Difficulty: Medium
Average Score: 89%
Practice
Gold in rheumatoid arthritis
Correct answer
B
Rationale
In the context of treating rheumatoid arthritis, the correct answer is B) Can reduce the concentrations of rheumatoid factor. Gold compounds, such as aurothiomalate and auranofin, were historically used to treat rheumatoid arthritis. These medications were believed to reduce rheumatoid factor levels, which are antibodies commonly found in the blood of individuals with rheumatoid arthritis. By reducing these antibodies, gold compounds were thought to help alleviate symptoms and slow disease progression.
Option A) Can cause regression of degenerative lesions of this disease is incorrect because gold compounds do not typically cause regression of degenerative lesions in rheumatoid arthritis. They are more focused on managing symptoms rather than reversing structural damage.
Option C) Does not halt the progress of the disease is incorrect as gold compounds were believed to have some disease-modifying effects, although they are not considered first-line treatments due to their side effect profile and the availability of more effective medications.
Option D) Is employed as first-line therapy is incorrect because gold compounds are not commonly used as first-line therapy for rheumatoid arthritis anymore. They have been largely replaced by other medications such as disease-modifying antirheumatic drugs (DMARDs) and biologics due to their more favorable risk-benefit profiles.
Educationally, this question highlights the historical context of rheumatoid arthritis treatment and the evolution of pharmacological management strategies. Understanding the mechanisms and limitations of different drug classes is crucial for healthcare professionals to make informed decisions when treating patients with rheumatoid arthritis.
Option A) Can cause regression of degenerative lesions of this disease is incorrect because gold compounds do not typically cause regression of degenerative lesions in rheumatoid arthritis. They are more focused on managing symptoms rather than reversing structural damage.
Option C) Does not halt the progress of the disease is incorrect as gold compounds were believed to have some disease-modifying effects, although they are not considered first-line treatments due to their side effect profile and the availability of more effective medications.
Option D) Is employed as first-line therapy is incorrect because gold compounds are not commonly used as first-line therapy for rheumatoid arthritis anymore. They have been largely replaced by other medications such as disease-modifying antirheumatic drugs (DMARDs) and biologics due to their more favorable risk-benefit profiles.
Educationally, this question highlights the historical context of rheumatoid arthritis treatment and the evolution of pharmacological management strategies. Understanding the mechanisms and limitations of different drug classes is crucial for healthcare professionals to make informed decisions when treating patients with rheumatoid arthritis.